---
title: "BridgeBio Pharma pre-market stock rises over 10%"
description: "BridgeBio Pharma pre-market in the US rose over 10%, currently reported at $59.96"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262876461.md"
published_at: "2025-10-27T11:06:23.000Z"
---

# BridgeBio Pharma pre-market stock rises over 10%

> BridgeBio Pharma pre-market in the US rose over 10%, currently reported at $59.96

Bridgebio Pharma's pre-market stock price rose over 10%, currently reported at $59.96

### Related Stocks

- [BBIO.US - Bridgebio Pharma](https://longbridge.com/en/quote/BBIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference | BridgeBio Pharma (NASDAQ:BBIO) presented at the J.P. Morgan Healthcare Conference, highlighting its ATTR-CM product, Att | [Link](https://longbridge.com/en/news/272361328.md) |
| BridgeBio Pharma (BBIO) Valuation Check After Insider Selling And Upcoming Infigratinib Trial Updates | BridgeBio Pharma (BBIO) faces scrutiny as insider selling coincides with upcoming catalysts, including a January 9 webin | [Link](https://longbridge.com/en/news/271695155.md) |
| BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing | BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing | [Link](https://longbridge.com/en/news/269985479.md) |
| BridgeBio Pharma Highlights Pipeline Progress and Patient Impact in New Corporate Presentation | BridgeBio Pharma Inc. has released a corporate presentation outlining its pipeline and strategy, focusing on first-in-cl | [Link](https://longbridge.com/en/news/272295165.md) |
| BUZZ-BridgeBio rises after $550 mln convertible debt offering | BridgeBio Pharmashares rose 0.5% to $76.63 after announcing a $550 million convertible debt offering. The company priced | [Link](https://longbridge.com/en/news/272850047.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.